RGNX insider trading
NasdaqGS HealthcareREGENXBIO Inc.: insider trade history from SEC Form 4 filings.
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Company website: www.regenxbio.com
RGNX insider activity at a glance
FilingIQ tracks 765 insider transactions for RGNX in filings since Sep 22, 2015. The most recent transaction is dated Sep 1, 2026.
Across the full history, 5 open-market purchases
and 437 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RGNX insider trades is 44.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RGNX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for RGNX?
- FilingIQ tracks 765 Form 4 insider transactions for RGNX (REGENXBIO Inc.), covering filings from Sep 22, 2015 onwards. 7 of those are dated within the last 90 days.
- Are RGNX insiders net buyers or net sellers?
- Across the full Form 4 history for RGNX, 5 transactions (1%) were open-market purchases and 437 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RGNX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is RGNX in?
- REGENXBIO Inc. (RGNX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $414.60M.
Methodology & sources
Every RGNX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.